

Cover Story
A demonstration project in which the Centers for Medicare& Medicaid Services hopes to investigate the impact of reimbursement based on Average Sales Prices of drugs is running into strong opposition, as a large number of cancer groups submitted public comments urging the agency to abandon the endeavor.
In Brief


Drugs & Targets
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- ASCO and Google Cloud set forth a vision for using AI to modernize health care and advance oncology
- The insinuation that AstroTurf causes GBM has no basis in science
The Philadelphia Inquirer series does disservice to brain tumor community - Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research